Table 1.

Patient characteristics

Age, y  
 Median 52 
 Range 20-65  
 Older than 60 (%) 15  (24) 
Sex (%)  
 Male 36  (58)  
 Female 26  (42) 
Stage (%)  
 I 2  (3)  
 II 3  (5) 
 III 19  (31)  
 IV 38  (61)  
Serum LDH (%)  
 Normal 3  (5)  
 Elevated 59  (95)  
ECOG performance status (%)  
 0/1 6/22  (45) 
 2/3/4 25/8/1  (55)  
Extranodal sites of disease (%)  
 None 9  (15)  
 One 23  (37)  
 Two or more 30  (48)  
IPI (%)  
 Low-intermediate, 2* 18  (29)  
 High-intermediate, 3* 21  (34)  
 High, 4-5* 23  (37) 
Age-adjusted IPI (%)  
 High-intermediate, 2* 36  (58)  
 High, 3* 26  (42) 
Histology (%)  
 Follicular large cell 3  (5) 
 Diffuse, mixed small and large cell 1  (2)  
 Diffuse large cell or immunoblastic 48/1  (79)  
 Diffuse small noncleaved cell 1  (2)  
 Other types 8  (13)† 
Age, y  
 Median 52 
 Range 20-65  
 Older than 60 (%) 15  (24) 
Sex (%)  
 Male 36  (58)  
 Female 26  (42) 
Stage (%)  
 I 2  (3)  
 II 3  (5) 
 III 19  (31)  
 IV 38  (61)  
Serum LDH (%)  
 Normal 3  (5)  
 Elevated 59  (95)  
ECOG performance status (%)  
 0/1 6/22  (45) 
 2/3/4 25/8/1  (55)  
Extranodal sites of disease (%)  
 None 9  (15)  
 One 23  (37)  
 Two or more 30  (48)  
IPI (%)  
 Low-intermediate, 2* 18  (29)  
 High-intermediate, 3* 21  (34)  
 High, 4-5* 23  (37) 
Age-adjusted IPI (%)  
 High-intermediate, 2* 36  (58)  
 High, 3* 26  (42) 
Histology (%)  
 Follicular large cell 3  (5) 
 Diffuse, mixed small and large cell 1  (2)  
 Diffuse large cell or immunoblastic 48/1  (79)  
 Diffuse small noncleaved cell 1  (2)  
 Other types 8  (13)† 

n = 62 patients.

*

Number of adverse prognostic factors.

†

Includes anaplastic large cell (n = 4), peripheral T cell (n = 1), high-grade Burkitt-like (n = 2), and T-cell–rich diffuse large cell lymphoma (n = 1).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal